Korea United Pharm Inc. (033270.KS) Financial Statements

Income statement

Metric	TTM	2025	2024	2023	2022
Revenue
Total Revenue	298.1B	288.8B	288.7B	278.9B	262.5B
Cost of Revenue	122.2B	113.4B	124.7B	120.0B	117.2B
Gross Profit	175.9B	175.4B	164.0B	159.0B	145.3B
Operating Expenses
R&D Expense	13.5B	34.4B	16.2B	33.2B	15.5B
SG&A Expense	30.5B	39.3B	38.9B	36.8B	34.7B
General & Admin Expense	12.5B	16.7B	15.9B	16.0B	16.1B
Selling & Marketing Expense	17.9B	22.6B	23.0B	20.7B	18.5B
Other Expenses	87.9B	52.7B	52.6B	34.1B	46.9B
Total Operating Expenses	127.0B	126.5B	107.7B	104.0B	97.1B
Cost and Expenses	248.6B	239.2B	232.4B	224.0B	214.3B
Operating Income (EBIT)	49.2B	48.9B	56.3B	54.9B	48.2B
Non-Operating
Interest Income	5.0B	4.7B	4.4B	6.7B	2.1B
Interest Expense	156.3M	173.6M	484.4M	1.6B	815.5M
Net Interest Income	4.8B	4.5B	3.9B	5.1B	1.3B
Other Non-Op Income/Expense	39.9B	911.5M	(10.2B)	5.1B	5.2B
Non-Operating Income (excl Interest)	(5.8B)	114.9M	9.7B	(5.7B)	(4.8B)
EBT (Pre-Tax Income)	89.6B	49.8B	46.1B	60.1B	53.4B
Income Tax Expense	13.5B	11.5B	13.6B	11.8B	8.1B
Bottom Line
Net Income	76.2B	38.3B	32.5B	48.3B	45.3B
Earnings from Cont. Ops	76.2B	38.3B	32.5B	48.3B	45.3B
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	76.2B	38.3B	32.5B	48.3B	45.3B
Per Share
Basic EPS	₩4,922	₩2,614	₩2,206	₩3,298	₩3,058
Diluted EPS	₩4,922	₩2,614	₩2,206	₩3,277	₩3,038
Revenue Per Share	₩18,734	₩17,679	₩19,651	₩19,061	₩17,730
Shares
Basic Shares Outstanding	15.9M	16.3M	14.7M	14.6M	14.8M
Diluted Shares Outstanding	15.9M	16.3M	14.7M	14.7M	14.9M
Profitability Metrics
EBITDA	65.0B	60.5B	57.8B	70.8B	61.8B
D&A	11.4B	11.6B	11.3B	10.1B	8.7B
EBIT	53.6B	48.9B	46.6B	60.7B	53.1B

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026